Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
15 Cards in this Set
- Front
- Back
|
Cortisone
|
Short to medium acting glucocorticoid
|
|
|
Hydrocortisone
|
Short to medium acting glucocorticoid used to treat adrenal insufficiency (15-20 mg AM and 5-10 mg PM)
|
|
|
Prednisone
|
Short to medium acting glucocorticoid used to treat adrenal insufficiency (5-7.5 mg daily)
Anyone who has recieved more than 20 mg of prednisone a day for more than three weeks should be assumed to have functional suppression of hypothalamic-pituitary-adrenal function. |
|
|
Prednisolone
|
Short to medium acting glucocorticoid
|
|
|
Methylprednisolone
|
Short to medium acting glucocorticoid
|
|
|
Dexamethasone
|
Long-acting glucocorticoid
|
|
|
Betamethasone
|
Long-acting glucocorticoid
|
|
|
Triamcinalone
|
Intermediate-acting glucocorticoid
|
|
|
Fludrocortisone
|
Mineralocorticoid
Add a mineralocorticoid (fludrocortisone) 0.05-0.1 mg daily to glucocorticoid in patients with primary adrenal insufficiency. |
|
|
Aminoglutethamide
|
An anticonvulsant drug that primarily blocks the first step in cortisol biosynthesis (cholestrol side-chain cleavage to pregnenolone).
|
|
|
Spironolactone
|
Blocks mineralocorticoid receptors and is used in hyperaldoseronism.
|
|
|
Eplerenone
|
Blocks mineralocorticoid receptors and is used in hyperaldoseronism.
|
|
|
Triamterene
|
Blocks Na+ conductance channel, reduces Na+ reabsorption and blood pressure.
|
|
|
What are glucocorticoids used to treat?
|
Antoimmune diseases, allergic states, organ transplantation, certain cancers, dermatological diseases, respiratory diseases, ophthalmic conditions, GI diseases, and nervous system problems
|
|
|
Ketoconazole
|
Ketoconazole (Nizoral) inhibits the first step in cortisol biosynthesis (side-chain cleavage) and to a lesser extent the conversion of 11-deoxycortisol to cortisol. It may be more effective than aminoglutethimide or metyrapone because it also inhibits ACTH secretion at therapeutic doses (200 to 400 mg two or three times a day) by impairing corticotroph adenylate cyclase activation. This is the most commonly used and is a first line agent.
|
